Results 31 to 40 of about 41,377 (182)
Journal of International Medical ResearchNirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Yinhua Gong +4 more
doaj +1 more source
Ritonavir Has Reproductive Toxicity Depending on Disrupting PI3K/PDK1/AKT Signaling Pathway
ToxicsRitonavir (RTV) is an antiviral and a component of COVID-19 treatments. Moreover, RTV demonstrates anti-cancer effects by suppressing AKT. However, RTV has cytotoxicity and suppresses sperm functions by altering AKT activity.
Eun-Ju Jung +7 more
doaj +1 more source
The effect of ritonavir on the pharmacokinetics of clonidine
Pakistan Journal of Pharmaceutical Sciences, 2023 This project aims to explore the repercussions of ritonavir on both the drug kinetics of clonidine in rats and clonidine metabolism in liver microsomes.
in vivo +4 more
doaj +1 more source
Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients
British Journal of Clinical Pharmacology, EarlyView.Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen +14 more
wiley +1 more source
CrystalsThe control of crystal polymorphs is central to the design of pharmaceuticals and functional materials. Conventionally, crystal polymorph production has been controlled primarily by adjusting chemical and thermodynamic parameters.
Yoshio Kondo +4 more
doaj +1 more source
GMS Ophthalmology Cases, 2013 [english] Objective: To report on a case of retinal pigment epithelium (RPE) toxicity apparently associated with ritonavir.Methods: We describe a case of gradual-onset blurry vision in both eyes in a 30-year-old HIV-positive male on Highly-Active ...
Santos, Luisa +4 more
doaj +1 more source
EClinicalMedicine, 2023 Summary: Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/
Jon Salmanton-García +115 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo +12 more
wiley +1 more source
Clinical Pharmacology: Advances and Applications, 2021 Marit Vermunt,1 Serena Marchetti,2 Jos Beijnen1,3,4 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 2Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066,
Vermunt M, Marchetti S, Beijnen J
doaj
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson +8 more
wiley +1 more source